Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration granted Priority Review for the supplemental Biologics...
Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended...
The new formulation was approved to help patients with tardive dyskinesia who have trouble swallowing.
Net product revenues for the first quarter 2024 totaled $359.5 million, a 55% increase over the same quarter of the prior year ELEVIDYS net revenues for the quarter totaled $133.9...
FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.